Dana-Farber Cancer Institute: CAR T-Cell Therapy Targeting GPRC5D Antigen Proves Effective In First Trial In Patients With Resistant Multiple Myeloma
September 29, 2022
September 29, 2022
BOSTON, Massachusetts, Sept. 29 (TNSjou) -- The Dana-Farber Cancer Institute issued the following news release on Sept. 28, 2022:
A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center and Roswell Park Comprehensive Cancer Center report in a new study.
The th . . .
A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center and Roswell Park Comprehensive Cancer Center report in a new study.
The th . . .